
Abeona reports Q1 2026 with rising ZEVASKYN treatments and new T-cell therapy licensing.
Abeona Therapeutics reported Q1 2026 financial results showing increased adoption of its cell therapy ZEVASKYN, treating three patients in the quarter and expanding its Qualified Treatment Center network to six sites. The company licensed a novel eng...

